Maureen Watt

616 total citations
35 papers, 368 citations indexed

About

Maureen Watt is a scholar working on Genetics, Epidemiology and Infectious Diseases. According to data from OpenAlex, Maureen Watt has authored 35 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Epidemiology and 11 papers in Infectious Diseases. Recurrent topics in Maureen Watt's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (12 papers), Clostridium difficile and Clostridium perfringens research (10 papers) and Microscopic Colitis (8 papers). Maureen Watt is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (12 papers), Clostridium difficile and Clostridium perfringens research (10 papers) and Microscopic Colitis (8 papers). Maureen Watt collaborates with scholars based in United Kingdom, United States and Germany. Maureen Watt's co-authors include Stephen Palmer, Mark Sculpher, Rachele Busca, Stuart Mealing, Stephen Mitchell, James Eaton, Jameel Nazir, Nicolò Piazza, Neil Moat and John Posnett and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Allergy and Clinical Immunology.

In The Last Decade

Maureen Watt

28 papers receiving 353 citations

Peers

Maureen Watt

EPIDE

SURGE

CCM

GENET

Darío Rubio-Rodríguez Spain

Laura Franco Italy

Rajesh Rajan Kuwait

Patrick Michael United States

Enric Grau Spain

Alexander Cohen United States

Ronan W. Hsieh United States

Olynka Vega‐Vega Mexico

Syed Ahsan Ali Pakistan

Eunyoung Suh United States

Darío Rubio-Rodríguez Spain

Maureen Watt

115 ×0.5

EPIDE

103 ×0.6

41 ×0.4

SURGE

116 ×1.2

CCM

28 ×0.6

GENET

Citations per year, relative to Maureen Watt Maureen Watt (= 1×) peers Darío Rubio-Rodríguez

Countries citing papers authored by Maureen Watt

Since Specialization

Citations

This map shows the geographic impact of Maureen Watt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen Watt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen Watt more than expected).

Fields of papers citing papers by Maureen Watt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maureen Watt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen Watt. The network helps show where Maureen Watt may publish in the future.

Co-authorship network of co-authors of Maureen Watt

This figure shows the co-authorship network connecting the top 25 collaborators of Maureen Watt. A scholar is included among the top collaborators of Maureen Watt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen Watt. Maureen Watt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zanichelli, Andrea, Walter A. Wuillemin, Emel Aygören‐Pürsün, et al.. (2025). Lanadelumab’s impact on hereditary angioedema control and quality of life across disease activity subgroups. Annals of Allergy Asthma & Immunology. 135(5). 560–569.e2.

Watt, Maureen, et al.. (2025). Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review. Drugs - Real World Outcomes. 12(3). 351–365.

Craig, Timothy, Raffi Tachdjian, Jonathan A. Bernstein, et al.. (2024). Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents. Annals of Allergy Asthma & Immunology. 133(6). 712–719.e1. 1 indexed citations

Watt, Maureen, et al.. (2024). Dogs receiving cyclooxygenase-2–sparing nonsteroidal anti-inflammatory drugs and/or nonphysiologic steroids are at risk of severe gastrointestinal ulceration. Journal of the American Veterinary Medical Association. 263(3). 1–8. 1 indexed citations

Watt, Maureen, Saeid Shahraz, Sara Costa-Cabral, et al.. (2023). Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema. Journal of Patient-Reported Outcomes. 7(1). 33–33. 7 indexed citations

Wedner, H. James, Jonathan A. Bernstein, Stephen Betschel, et al.. (2023). Effectiveness, Safety, and Patient-Reported Outcomes (PROs) in Patients With Hereditary Angioedema (HAE) From the United States and Canada Treated With Lanadelumab: 24-Month Data From the EMPOWER Study. Journal of Allergy and Clinical Immunology. 151(2). AB131–AB131. 4 indexed citations

Watt, Maureen, Marcus Maurer, William R. Lumry, et al.. (2023). Health-Related Quality of Life (HRQoL) in Pediatric Patients with Hereditary Angioedema (HAE) Receiving Lanadelumab: Exploratory Results From the SPRING Study. Journal of Allergy and Clinical Immunology. 151(2). AB139–AB139.

Lumry, William R., Marcus Maurer, Karsten Weller, et al.. (2023). Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. Annals of Allergy Asthma & Immunology. 131(1). 101–108.e3. 11 indexed citations

Maurer, Marcus, William R. Lumry, H. Henry Li, et al.. (2023). Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study. The Journal of Allergy and Clinical Immunology In Practice. 12(1). 201–211.e6. 15 indexed citations

10.

Watt, Maureen, et al.. (2017). "De-escalation" strategy using micafungin for the treatment of systemic <em>Candida</em> infections: budget impact in France and Germany. ClinicoEconomics and Outcomes Research. Volume 9. 763–774. 4 indexed citations

11.

Mitchell, Stephen, et al.. (2017). A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. PharmacoEconomics. 35(11). 1123–1140. 30 indexed citations

12.

Watt, Maureen, et al.. (2016). A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection. 44(5). 599–606. 33 indexed citations

13.

Rubio-Terrés, Carlos, Javier Cobo Reinoso, Santiago Grau Cerrato, et al.. (2015). Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. European Journal of Clinical Microbiology & Infectious Diseases. 34(11). 2213–2223. 29 indexed citations

14.

Watt, Maureen, et al.. (2015). A Cost-effectiveness and Budget Impact Analysis of Fidaxomicin for Treating Clostridium Difficile Patients In Germany. Value in Health. 18(3). A233–A233. 1 indexed citations

15.

Asensio, Ángel, Stefano Di Bella, Andrea Lo Vecchio, et al.. (2015). The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. International Journal of Infectious Diseases. 36. 31–38. 28 indexed citations

16.

Perera, S., et al.. (2014). Economic Evaluation Of Fidaxomicin Compared With Vancomycin In The Treatment Of Clostridium Difficile Infection. Value in Health. 17(3). A270–A270. 1 indexed citations

17.

Mealing, Stuart, Isabella Ghement, Neil Hawkins, et al.. (2014). The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Systematic Reviews. 3(1). 21–21. 4 indexed citations

18.

Hart, W. M., et al.. (2013). The Burden of Clostridium Difficile in Spain: A Retrospective Matched-Cohort Study. Value in Health. 16(7). A349–A349. 1 indexed citations

19.

Watt, Maureen, Stuart Mealing, James Eaton, et al.. (2011). Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart. 98(5). 370–376. 86 indexed citations

20.

McCarron, Mark O., et al.. (2003). Left internal carotid artery dissection presenting with headache, Collet‐Sicard syndrome and sustained hypertension. European Journal of Neurology. 10(6). 731–732. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact